Core Concepts
Multimodality approaches like FLOT and CROSS trials show similar outcomes for GEJ cancers.
Stats
In the last two decades, the incidence of gastroesophageal junction (GEJ) adenocarcinomas (AC) has increased.
Neoadjuvant therapy with chemotherapy and radiation (RT) followed by surgery is now considered standard practice for most esophageal cancers.
Peri-operative chemotherapy with epirubicin-based triplet chemotherapy showed improvement in OS for patients with locally advanced gastric cancer.
The new standard of care for gastric cancer has become another triplet chemotherapy regimen with fluorouracil, leucovorin, oxaliplatin, docetaxel (FLOT).
Quotes
"GECs rank 2nd highest in global cancer mortality."
"Tri-modality treatment has significantly improved R0 resection rates and overall survival (OS)."